Evolution of Substance use, Neurological and Psychiatric Symptoms in Schizophrenia and Substance use Disorder Patients: A 12-Week, Pilot, Case-Control Trial with Quetiapine.
about
Plasma Endocannabinoid Alterations in Individuals with Substance Use Disorder are Dependent on the "Mirror Effect" of SchizophreniaIs the deficit in pain inhibition in fibromyalgia influenced by sleep impairments?Predictors of community functioning in schizophrenia and substance use disorder patients.Is it time to consider comorbid substance abuse as a new indication for antipsychotic drug development?
P2860
Evolution of Substance use, Neurological and Psychiatric Symptoms in Schizophrenia and Substance use Disorder Patients: A 12-Week, Pilot, Case-Control Trial with Quetiapine.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Evolution of Substance use, Ne ...... Control Trial with Quetiapine.
@ast
Evolution of Substance use, Ne ...... Control Trial with Quetiapine.
@en
Evolution of Substance use, Ne ...... Control Trial with Quetiapine.
@nl
type
label
Evolution of Substance use, Ne ...... Control Trial with Quetiapine.
@ast
Evolution of Substance use, Ne ...... Control Trial with Quetiapine.
@en
Evolution of Substance use, Ne ...... Control Trial with Quetiapine.
@nl
prefLabel
Evolution of Substance use, Ne ...... Control Trial with Quetiapine.
@ast
Evolution of Substance use, Ne ...... Control Trial with Quetiapine.
@en
Evolution of Substance use, Ne ...... Control Trial with Quetiapine.
@nl
P2093
P2860
P356
P1476
Evolution of Substance use, Ne ...... Control Trial with Quetiapine.
@en
P2093
Alain Gendron
Elie Rizkallah
Jean-Pierre Chiasson
Joelle Desfossés
Lahcen Aït Bentaleb
Olivier Lipp
Pierre-Paul Rompré
Simon Zhornitsky
Tania Pampoulova
P2860
P356
10.3389/FPSYT.2011.00022
P577
2011-05-13T00:00:00Z